BiBBInstruments AB ("BiBB" or the "Company"), developer of EndoDrill® - the world's first market-cleared powered biopsy instrument for endoscopy - announces today that it has received its second order from distribution partner Palex Medical Spain. The order is valued at EUR 12,000 (≈ SEK 132 thousand) and follows the initial order of EUR 15,600 (≈ SEK 178 thousand) placed in July and the subsequent launch in September. In parallel, BiBB is in discussions regarding distribution agreements with additional companies within the Palex Group network.
Comment from Fredrik Lindblad, CEO of BiBB:
"We are very pleased to receive a repeat order for EndoDrill® GI from our new distribution partner in Spain. We view this repeat order as an encouraging signal after the initial clinical activities at Spanish hospitals and as an important step in the ongoing launch in our first European market."
About Palex Group and Palex Medical Spain
Palex Group is a leading European distributor of healthcare and medical technology products, providing advanced solutions and services to hospitals, healthcare professionals, and research institutions. The group operates through a network of specialized companies with expertise in endoscopy, surgery, interventional medicine, and hospital solutions. Palex Spain is the largest operating company within Palex Group, with nearly 1,000 employees and a dedicated endoscopy organization working with leading hospitals throughout Spain.
About EndoDrill® GI
EndoDrill® GI is the world's first market-cleared powered biopsy instrument for endoscopic ultrasound (EUS), with both FDA 510(k) clearance and CE marking. Unlike conventional manual biopsy needles, EndoDrill® GI uses a powered, rotating drill tip designed to obtain intact tissue cores for histopathological and molecular analysis. The system is currently being commercialized in the United States through distribution partner TaeWoong Medical USA. The commercial launch in Europe is now underway in Spain through distribution partner Palex Medical Spain, representing the first step in BiBB's European expansion.
For more information about BiBB, please contact:
Fredrik Lindblad, CEO
Email: fredrik.lindblad@bibbinstruments.com
Phone: +46 70 899 94 86
This information was submitted for publication, through the agency of the contact person set out above, at the time specified by the Company's news distributor upon publication of this press release.
About BiBBInstruments AB
BiBBInstruments AB is a cancer diagnostics company that develops and manufactures EndoDrill®, the world's first product family of market-cleared powered biopsy instruments for endoscopy. EndoDrill® is designed to obtain tissue samples in the form of intact tissue cores (core needle biopsies, CNB) for histopathological and molecular analysis, with the aim of improving cancer diagnostics in organs including the stomach, pancreas, liver, lungs, and urinary bladder. The product portfolio targets the global market for ultrasound-guided endoscopic biopsy instruments (EUS/EBUS), a growing segment within modern endoscopy. BiBB received FDA 510(k) clearance for EndoDrill® GI in 2023 and CE marking under the MDR for EndoDrill® GI, EndoDrill® EBUS, and EndoDrill® URO in 2024. EndoDrill® GI is thus the first powered biopsy instrument for endoscopy to obtain market clearance in both the United States and Europe. The US launch of EndoDrill® GI began in the second half of 2025 in collaboration with TaeWoong Medical USA, followed by the start of the European launch in Spain in autumn 2026 in collaboration with Palex Medical Spain. The EndoDrill® system consists of sterile single-use instruments and a proprietary drive system. BiBB was founded in 2013 by Dr Charles Walther, a cancer researcher at Lund University and senior consultant in pathology at Skåne University Hospital. The Company is headquartered at Medicon Village in Lund, Sweden, and its shares are listed on Spotlight Stock Market (ticker: BIBB).